Ask AI
ProCE Banner Activity

Breaking the Therapeutic Ceiling: Emerging Treatments for Schizophrenia Care

Podcast

In this episode, Dr Leslie Citrome reviews how recent advances in schizophrenia research have expanded our understanding of disease neurobiology and introduced novel therapeutic mechanisms beyond dopamine receptor blockade. Through a review of current clinical evidence, this episode explores emerging therapies, with a focus on muscarinic-targeted treatments, including their safety and tolerability profiles as well as practical strategies for incorporating these advances into the care of adults with schizophrenia.

Released: August 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb. 

Bristol Myers Squibb

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate dopaminergic and muscarinic mechanisms of actions of novel therapies, and explain the clinical utility to address unmet needs of patients with schizophrenia

  • Evaluate emerging clinical evidence supporting novel therapies in schizophrenia, with attention to efficacy signals, safety considerations, and current limitations of the data

  • Design strategies to integrate novel therapeutic options into treatment plans for patients with schizophrenia while counseling them on optimal administration and side effect management

Financial Disclosures

Primary Author

Leslie Citrome, MD, MPH: consultant: AbbVie, Acadia, AdhereTech, Alkermes, Altus, Alumis, Arc, Auritec, Autobahn, Avant Healthcare Solutions, Axsome, Biogen, BioXcel, Bristol Myers Squibb/Karuna, Boehringer Ingelheim, Cadent, Cerevel, Clario/Medavante/Prophase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health Wellness Partners, HLS Therapeutics, Idorsia, INmune Bio, Intra-Cellular, Johnson & Johnson/Janssen, Little Bear, Lundbeck, Luye, Lyndra, MapLight, Marvin, Mindmed, Neumora, Neurocrine, Neurelis, Neushen, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo/Sunovion, Supernus, Teva, Vanda; speaker: AbbVie, Acadia, Alkermes, Bristol Myers Squibb, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, Vanda; individual publicly traded stock/stock options: Reviva.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.